Thermo Fisher Scientific Inc

Valuation Analysis

About the Company

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as

Thermo Fisher Scientific Inc Stock at a Glance

Thermo Fisher Scientific Inc (TMO) is currently trading at $469.34 with a market capitalization of $174.4B. The trailing P/E ratio stands at 25.77x, with a forward P/E of 17.22x. The 52-week range spans from $385.46 to $643.99; the current price is 27.1% below the yearly high. Year-over-year revenue growth stands at +6.2%. The net profit margin stands at 15.15%.

💰 Dividend

Thermo Fisher Scientific Inc pays an annual dividend of $1.88 per share, representing a yield of 0.4%. The payout ratio stands at 9.68%.

📊 Analyst Rating

26 analysts rate Thermo Fisher Scientific Inc (TMO) on consensus: Buy. The average price target is $599.19, implying +27.67% from the current price. Analyst price targets range from $490.00 to $750.00.

Thermo Fisher Scientific Inc: The Investment Case in Detail

Thermo Fisher Scientific Inc (TMO) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

The combination of a 40.93% gross margin and 17.89% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 15.15%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 27.67% upside from current levels — analyst sentiment is firmly constructive.

What to Watch Next

• The forward P/E of 17.22x is meaningfully below the trailing 25.77x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 27.67% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Thermo Fisher Scientific Inc?

Compare top-rated brokers — low fees, trusted providers, fully regulated.